Tisagenlecleucel for neoplasm, residual

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Mar 2019: Trial registered, NCT03876769
  2. 24 Jun 2019: Trial started, NCT03876769

The trials

NCT03876769: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

State
Under way
Phase
Phase 2
People
121 taking part
Started
24 Jun 2019
Primary completion
19 Oct 2027
Arms
Single dose of CTL019
Results
None posted
  1. 15 Mar 2019: Trial registered
  2. 24 Jun 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as CART-19 cells, CTL019 T-cells, Kymriah.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.